Safety of olanzapine.J Clin Psychiatry. 1997; 58 Suppl 10:13-7.JC
Abstract
Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized. The primary clinical trial safety database included 2500 patients treated with olanzapine, 810 with haloperidol, and 236 with placebo. The overall discontinuation rate from olanzapine treatment was low. Significant adverse events included somnolence, weight gain, and asymptomatic treatment-emergent transaminase elevation. Minimal parkinsonism and akathisia with rare dystonia were noted. No hematotoxicity was noted. The incidence of seizures and sexual dysfunction was rare.
Links
MeSH
Acute DiseaseAkathisia, Drug-InducedAntipsychotic AgentsBenzodiazepinesBlood PressureClinical Trials as TopicCross-Over StudiesDizzinessDouble-Blind MethodDystoniaHaloperidolHeart RateHumansLiverOlanzapineParkinson Disease, SecondaryPirenzepinePlacebosPsychiatric Status Rating ScalesRandomized Controlled Trials as TopicSchizophreniaSchizophrenic PsychologySleepTransaminasesTreatment OutcomeWeight Gain
Pub Type(s)
Comparative Study
Journal Article
Meta-Analysis
Language
eng
PubMed ID
9265911
Clinical Trial Links
Citation
Beasley, C M., et al. "Safety of Olanzapine." The Journal of Clinical Psychiatry, vol. 58 Suppl 10, 1997, pp. 13-7.
Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58 Suppl 10:13-7.
Beasley, C. M., Tollefson, G. D., & Tran, P. V. (1997). Safety of olanzapine. The Journal of Clinical Psychiatry, 58 Suppl 10, 13-7.
Beasley CM, Tollefson GD, Tran PV. Safety of Olanzapine. J Clin Psychiatry. 1997;58 Suppl 10:13-7. PubMed PMID: 9265911.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Safety of olanzapine.
AU - Beasley,C M,Jr
AU - Tollefson,G D,
AU - Tran,P V,
PY - 1997/1/1/pubmed
PY - 2001/3/28/medline
PY - 1997/1/1/entrez
SP - 13
EP - 7
JF - The Journal of clinical psychiatry
JO - J Clin Psychiatry
VL - 58 Suppl 10
N2 - Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized. The primary clinical trial safety database included 2500 patients treated with olanzapine, 810 with haloperidol, and 236 with placebo. The overall discontinuation rate from olanzapine treatment was low. Significant adverse events included somnolence, weight gain, and asymptomatic treatment-emergent transaminase elevation. Minimal parkinsonism and akathisia with rare dystonia were noted. No hematotoxicity was noted. The incidence of seizures and sexual dysfunction was rare.
SN - 0160-6689
UR - https://www.unboundmedicine.com/medline/citation/9265911/Safety_of_olanzapine_
L2 - http://www.psychiatrist.com/jcp/article/pages/1997/v58s10/v58s1003.aspx
DB - PRIME
DP - Unbound Medicine
ER -